The Centers for Medicare & Medicaid Services (CMS) announced October 9 in a decision memo that it will cover the Colorguard™ test — a multitarget stool DNA test — as a colorectal cancer screening test.
The Colorguard™ test will be covered under Medicare Part B once every three years for asymptomatic, average risk beneficiaries, aged 50 to 85 years.
An effective coverage date was not provided in the decision memo
. Watch for the national coverage determination for complete details.
The U.S. Preventive Services Task Force recommends the following parameters for colorectal cancer screening:
|Adults, beginning at age 50 years and continuing until age 75 years
||The USPSTF recommends screening for colorectal cancer using fecal occult blood testing, sigmoidoscopy, or colonoscopy in adults, beginning at age 50 years and continuing until age 75 years. The risks and benefits of these screening methods vary.
(High certainty of benefit)
|Adults age 76 to 85 years
||The USPSTF recommends against routine screening for colorectal cancer in adults 76 to 85 years of age. There may be considerations that support colorectal cancer screening in an individual patient.
(Moderate certainty of benefit)
|Adults older than age 85 years
||The USPSTF recommends against screening for colorectal cancer in adults older than age 85 years.
(High certainty of no benefit)
|Computed Tomographic Colonography and Fecal DNA testing as screening modalities
||The USPSTF concludes that the evidence is insufficient to assess the benefits and harms of computed tomographic colonography and fecal DNA testing as screening modalities for colorectal cancer.
(Evidence is insufficient)